Connect with us

BioPharma

Human Unitec International, inc (OTCMKTS: HMNU) Heating Up & Running Northbound After Co Announces Sale of 900 HMNU MSK Kinesis Medical Machines at $39k Each

Published

on

Human Unitec International, inc (OTCMKTS: HMNU) more than doubled on Wednesday after the Company reported three strategic marketing agreements for its HMNU-MSK Kinesis Medical Equipment. The three entities have agreed to an annual sale of 900 HMNU MSK Kinesis medical machines at a minimum cost of 39,000 USD each for a minimum annual revenue in excess of Thirty Million USD. The news brought some life into HMNU which was languishing at half a cent just over its $0.033 52-week lows. HMNU does have runner in its blood running to highs of $0.055 in June 2021 making a number of similar moves over the years. 

HMNU has a super low float with just 881,930,000 shares outstanding, 489,246,567 of which are restricted leaving just 392,683,433 free trading shares worth under $2 million at current market levels. HMNU has $2.4 million in the treasury and $20 million in investments vs. a $21.7 million deffered note payable. For the 3 months ended March 31, the Company reported revenues of $358,000 and a net income of $98,860.00 compared to $59,860.00 for the prior quarter. The $39 million in revenues from the Company’s HMNU-MSK Kinesis Medical Equipment will augment current sales very nicely. 

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Human Unitec International, inc (OTCMKTS: HMNU) operating out of Hudson, NY, is a Project Finance, Management & Development Company engaged in Medical, Wellness, and Green Energy. The Company is “pink current” and listed on the US OTC Market. With support of seasoned and experienced managements the Company has evolved into an international finance and management company with a number of diversified investments and is leader in Medical & Wellness and Green Energy industries. This decision of diversified investment was based on the acquisition of activities in cooperation and joint venture with the founders and operating management of the new venture. 

HMNU is a leader on the Green Energy industry as builder of a 20 tons tires and or plastic recycling plat, unique for technology and price on the global market. In 2020, the Company delivered the first innovative 20 Tons plant to Sedda Green Energy srl in Porto Torres, Italy. 

HMNU is a leader on the medical industry for its MSK Kinesis Technology and protocols for pain management therapies. The therapies and the protocols have been adopted for a range of medical treatments for pain management, Parkinson disease, treatment of blood clots and thrombosis. 

The Company is led by its new President, Kurt M. Gaensel, a seasoned executive who was a Business Development Manager for German Expansion Office Plastics & PCB. Contracted to relocate to Frankfurt Germany to open up an expansion office to target the European Automobile Market for Injection Molding and Printed Circuit Board business. In 2012 sales from Europe was at 8 million and by end 2017 Sales grew to 28 million. Setup business operations and develop account structure with our Inside Sales team in India and Germany. Traveled to customers, Tier 1-2 suppliers in all of Europe for meetings. Manage material procurement, Inventory Control and MRP for customers production. Oversee the Supply Chain and Logistics to ensure parts arrive in time for production.  

To Find out the inside Scoop on HMNU Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

HMNU

HMNU stock more than doubled on May 25 after the Company reported three strategic marketing agreements for its HMNU-MSK Kinesis Medical Equipment. On May 24, 2022, after the result of four years of corroboration, testing and equipment design, HMNU signed an agreement with Compagnia del Cavallo s.r.l. and its President Sergio Tramontano as the exclusive agent for Europe of the MSK Kinesis equipment and treatment protocols for vetinary medicine, 

On May 24, 2022, HMNU signed an agreement with Prof. Dr. Francesco Braconaro, Dr Orthopedic, Medical Director Maugeri Group-ICS, Milano, Italy; President Medical Board HMNU MEDICAL and Physician for National Team of Italy to market the sports medicine equipment from HMNU-MSK Kinesis. Also on May 24, 2022, HMNU Signed an agreement with Dr. Amir Ghazy Mir Saeid, Milano Physiotherapy Doctor, Specialist in sport medicine and traumatology. Dr. Saied has been appointed as the exclusive Italian Representative for HMNU Medical sport departments in Italy. 

The three entities have agreed to an annual sales of 900 HMNU MSK Kinesis medical machines at a minimum cost of 39,000 USD each for a minimum annual revenue in excess of Thirty Million USD. 

These agreements were finalized with the Human Unitec launch of its new generation of its medical and wellness equipment designed for use in the European market. The design of this new line is the result of our MSK Kinesis teams years of study and from the successful treatments on patients for treatment of Parkinson diseases, prevention of blood clots and thrombosis dysfunctions. The equipment is made with ABS and Environmental Protection materials. The HMNU/MSK equipment has been EU and CE tested and approved for wellness, medical, sports and veterinary use. 

For More on HMNU Subscribe Right Now!

HMNU is rocketing up the charts after the Company reported three strategic marketing agreements for its HMNU-MSK Kinesis Medical Equipment. The three entities have agreed to an annual sales of 900 HMNU MSK Kinesis medical machines at a minimum cost of 39,000 USD each for a minimum annual revenue in excess of $30 million USD. As we stated, HMNU has a super low float with just 881,930,000 shares outstanding, 489,246,567 of which are restricted leaving just 392,683,433 free trading shares worth under $2 million at current market levels. Currently HMNU is under heavy accumulation as penny stock speculators bid up the price with an eye on $0.055 recent highs.  We will be updating on HMNU when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with HMNU.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in HMNU either long or short and we have not been compensated for this article.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

BioPharma

Organogenesis (NASDAQ: ORGO): Latest Developments and Future Growth Prospects

Published

on

Organogenesis Holdings (NASDAQ: ORGO), a top regenerative medicine company dedicated to advanced wound care, surgical, and sports medicine solutions, gains over 30% during intraday trading and after hours combined after their latest release. According to the release, three Medicare Administrative Contractors (MACs) decided to withdraw certain coverage rules that were meant to start on October 1. These rules related to products for treating diabetic foot ulcers (DFU) and venous leg ulcers (VLU).

More Background:

Organogenesis serves a range of clients, from hospitals and wound care centers to doctors’ offices. The MACs’ initial rules, set on August 9, caused concern. They specified that covered products must be particular types of skin substitutes. Unfortunately, this excluded five products from Organogenesis, impacting their financial outlook.

Fast forward, the MACs pulled back these rules just in time, preventing potential harm to Organogenesis. Even before these rules, the company was facing challenges. In the second quarter, revenue was slightly down compared to the same period last year. Despite this, the company is doing better than the previous year in a six-month comparison.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Gary S. Gillheeney, Sr., the head of Organogenesis, expressed deep gratitude for the MACs and the Centers for Medicare & Medicaid Services (CMS). He praised their thoughtful consideration of stakeholder concerns and putting patients first. This decision will positively affect the lives of many.

He also thanked the stakeholders, including doctors, patient advocacy groups, and various associations. Their unified support played a vital role in challenging these rules, considering the potential harm they could cause patients. Their advocacy shed light on the possible negative health outcomes and treatment disparities, especially for those with higher rates of diabetes and related conditions. Their collective efforts made a significant difference.

We will update you on ORGO when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by Parentingupstream from Pixabay

Continue Reading

BioPharma

Vaccitech (NASDAQ: VACC) Gains Unprecedented Support—What’s Behind It?

Published

on

On September 25, 2023, Vaccitech (NASDAQ: VACC) experienced a jaw-dropping 90% surge in its stock price in just one day of trading. Now, this kind of jump usually happens when a company drops a major announcement or puts out a significant SEC filing. But, surprise, surprise—there was nothing of that sort this time .So naturally we did some digging, explored further online and guess what? Turns out retail traders were also not on a main reason for this rollercoaster ride. Curious to uncover what’s really behind this financial rollercoaster? Before we go any further, let’s get to know Vaccitech a bit better. There’s some pretty important aspects on the company you might like.

 

Background:

Vaccitech operates as a clinical-stage biopharmaceutical company, dedicated to discovering and developing innovative T cell immunotherapies. These therapies are crafted to leverage the immune system’s potency for treating conditions like chronic infectious diseases, cancer, and autoimmune disorders.

What sets Vaccitech apart is their distinctive, multi-platform approach, demonstrating the capacity to generate higher quantities of T cells compared to alternative technologies. This places Vaccitech in a unique position to cater to the needs of substantial, yet underserved patient populations. Their diverse clinical-stage pipeline includes potential treatments for severe diseases with limited available treatments, presenting significant public health risks.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Among their lead product candidates are VTP-300, an immunotherapeutic designed to contribute to a potential functional cure for chronic hepatitis B viral (HBV) infection. Additionally, VTP-200 is a non-invasive, early-stage investigational treatment targeting persistent, high-risk human papillomavirus (HPV). VTP-850 stands out as a novel T cell investigational therapy aimed at prostate cancer, while VTP-1000, a preclinical T cell therapeutic candidate, focuses on reinstating immune tolerance in celiac disease.

Vaccitech possesses well-established expertise in drug development and scientific knowledge within the immunization realm. Notably, they co-developed a COVID-19 vaccine in collaboration with the University of Oxford. As many of you know, their vaccine has been successfully approved and holds an exclusive license worldwide with AstraZeneca.

What happened:

The one and only thing that happened today was Alliance Global Partners adding coverage of Vaccitech with a favourable buy recommendation.What’s truly eye-catching are the projections made, suggesting some pretty significant upside. The average one-year price target for Vaccitech is $12.24. Forecasts within this period have a bit of a spectrum, reaching from a low estimate of $7.07 to a high of $15.75. With that said, from today’s closing price that’s nearly 400% gain.

What’s The Big Deal?:

Alliance Global Partners giving the green light to cover Vaccitech is like a thumbs-up from a respected expert. It’s like a top-tier food critic saying, “This restaurant is a must-try.”

Think of it as Vaccitech stepping into the spotlight. It’s like a talented musician getting featured on a famous music blog—suddenly, more people start paying attention.

When a big player like Alliance Global Partners says, “Hey, this stock is a good buy,” it’s like a friend recommending a must-watch movie. You’re more likely to check it out based on that suggestion.

This kind of recommendation can also affect the stock price. It’s similar to when a popular influencer talks about a cool product—lots of people want to try it.

In a nutshell, this coverage is like a stamp of approval, making Vaccitech catch the attention of more potential investors and possibly giving the stock a boost. But it’s important to mention that just because a well established financial firm gives a price target, does not mean it’s accurate. In fact, tons of these projections are made daily with many being totally off the mark. Always do your own due diligence.

We will update you on VACC when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by spencerbdavis1 from Pixabay

 

 

 

Continue Reading

BioPharma

Advancing Medical Frontiers: Elutia Inc.’s(NASDAQ: ELUT) Strategic Vision in a $600 Million Market

Published

on

Elutia Inc (NASDAQ: ELUT) shares bolstered a whopping 33% today as the company recently shared that they’ve secured about $10.5 million in funding through a private investment round. If all the warrants are cashed in as part of this funding, the total could go up to $26.2 million.

Latest Changes:

Just last week, Aziyo Biologics changed its name to Elutia Inc. Following this change, Elutia made an announcement about selling its Orthobiologics business unit to Berkeley Biologics, a subsidiary of GNI Group Ltd. This move is set to bring in a substantial amount of cash, totalling up to $35 million for Elutia. This sum includes a notable upfront payment of $15 million, plus additional potential earnings of up to $20 million over five years. The deal is expected to be finalized in the fourth quarter of 2023.

This sale is a big step for Elutia, especially in the realm of drug-eluting biomatrix technology (DEB). Elutia is actively seeking approval from the FDA for their main product, CanGaroo RM. This product utilizes innovative biomatrix technology with antibiotics rifampin and minocycline (RM), providing long-term protection for cardiac pacemakers and defibrillators. This tackles a huge market estimated to be worth around 600 million. Elutia is aiming to introduce CanGaroo RM to the market in the first half of 2024.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below. 

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Standard Of Care:

Medtronic (NYSE: MDT) stands as the exclusive provider of the antibiotic envelope within the current market. This envelope is crafted using synthetic mesh infused with antibiotics. Back in 2014, Medtronic acquired this technology, making a strategic investment of up to $200 million. Primarily intended for Cardiac Implantable Electronic Device (CIED) revision procedures, this product boasts estimated annual sales in the range of $250 to $300 million.

However, despite its market presence and revenue generation, the Medtronic antibiotic envelope has notable limitations. While it effectively combats infections, its synthetic composition renders it less effective in supporting wound healing. Moreover, it poses challenges in accommodating larger devices like Subcutaneous Implantable Defibrillators (SCID).

Drug-eluting biomatrix (DEB):

Drug-eluting biomatrix (DEB) involves a specialized approach to drug delivery using a biomatrix as a carrier or platform. In simple terms, it’s a technique where a biomaterial matrix, often a biocompatible polymer or similar substance, is used to release drugs in a controlled and targeted manner.

The biomatrix acts as a support structure that can hold and gradually release drugs or therapeutic agents at a specific site in the body, typically over an extended period. This is particularly useful in medical applications where a localized and sustained delivery of medication is necessary.

For instance, in the context of Elutia’s CanGaroo RM, a biomatrix incorporating antibiotics rifampin and minocycline is used to provide prolonged protection for cardiac pacemakers and defibrillators. The biomatrix slowly releases these antibiotics at the surgical site, preventing infections and promoting healing.

DEB technology is gaining traction because it enhances treatment efficiency by ensuring the drug is delivered directly to the target area, minimizing side effects, and optimizing therapeutic outcomes. It’s a promising approach in the field of medical advancements, especially in areas like cardiology, oncology, and orthopedics.

Post-mastectomy Breast Reconstruction:

On top of this, the company also has plans to develop an RM version of its SimpliDerm biomatrix tailored for breast reconstruction procedures. The rate of infections after this surgery is quite high, more than 10%, highlighting a big medical need in a market valued at over $500 million. Elutia is stepping up to address this issue by developing SimpliDerm® RM, which incorporates their unique DEB technology. The funds raised through the private investment round (PIPE) and the sale of the Orthobiologics business unit will not only boost Elutia’s efforts in advancing their drug-eluting biomatrix products for the cardiac pacemaker and defibrillator market, but also for post-mastectomy breast reconstruction.

What’s next:

As mentioned earlier, their biomatrix platform serves two major markets. CanGaroo RM, their upcoming product, is slated for a 1H of 2024 market release and is poised to be a pioneer in a $600 million market. Furthermore, their SimpliDerm RM product utilizes the same proprietary antibiotic-eluting technology found in CanGaroo RM, which serves a 1.6B market according to their presentation deck. They aim to secure an IDE by Q4 2024, and upon achieving these milestones, they plan to venture into neurostimulator markets, particularly in pain management, to further drive their growth.

We will update you on ELUT when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by sasint from Pixabay

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.